UPClytics
View all cases

UPC CFI 722/2025

Aug 8, 2025·EP3784233 Unitary patent · METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS

Case details
Status
Case Closed
Action
Revocation
Category
Main revocation action
Parties
Claimants
Representatives
Respondents
Representatives
Division
Milan CD
Technology
  • Chemistry
    Organic fine chemistry · Pharmaceuticals
Language
English
First decided
Mar 13, 2026
EPO Opposition
How this compares
The court's record for this kind of case, counted in first-instance rulings. A figure in brackets is the number of rulings a rate rests on.
Patent revokedMedian days to first decision
All UPC37% (34/91)124
Milan CDLockedLocked
Judge Andrea PostiglioneLockedLocked
Judge Marije KnijffLockedLocked
Judge Andreas Gustafsson—Locked

At the UPC: Neurocrine Biosciences, Inc. (1 case)·Spruce Biosciences, Inc. (1 case)

Decisions
  • 2026-03-13
    Revocation ActionPublic

    Summary: The Milan Central Division ordered disposal of Neurocrine Biosciences' revocation action (R. 360 RoP) against EP 3 784 233 because the patent had been definitively and entirely revoked by the EPO Opposition Division, rendering the revocation action devoid of purpose. Neurocrine's conditional request (disposal only if Spruce undertook not to enforce divisional patents) was held outside R. 360 RoP. Spruce (claimant/respondent) was ordered to pay 80% of maximum recoverable costs (EUR 488,000) to Neurocrine; Neurocrine was reimbursed 60% of court fees (EUR 12,000).

    Show the legal issues (4)
    • Disposal of proceedings where patent revoked by EPO (R. 360 RoP)
    • No-need-to-adjudicate order
    • Costs allocation (Art. 69 UPCA)
    • Court fee reimbursement
Document titleDatePublic
Communication2026-03-16Not public
Case closed2026-03-13Not public
Decision2026-03-13Not public
Decision2026-03-13Public
Receipt2026-02-26Not public
Cover sheet2026-02-26Not public
Document Claimant2026-02-26Not public
Communication2026-02-19Not public
Receipt2026-02-17Not public
Cover sheet2026-02-17Not public